7-Isopropyl-6-oxa-bicyclo[3.2.0]heptane | 29570-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 7-Isopropyl-6-oxa-bicyclo[3.2.0]heptane
• 英文别名: 7-Propan-2-yl-6-oxabicyclo[3.2.0]heptane
• CAS: 29570-05-6
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: NXWXALRVMYSMMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US10364234B2

  公开（公告）日：2019-07-30

  Pyridinecarboxamide derivatives, preparation methods, and a pharmaceutical uses thereof are provided. In particular, pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification are provided. Also provided are a preparation method for the pyridinecarboxamide derivatives of formula (I), a pharmaceutical composition containing the pyridinecarboxamide derivatives, and uses of the pyridinecarboxamide derivatives as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing hypertension and heart failure.

  本发明提供了吡啶甲酰胺衍生物、制备方法及其制药用途。特别是提供了由通式（I）代表的吡啶甲酰胺衍生物，其中式（I）的取代基在说明书中定义。还提供了式(I)吡啶甲酰胺衍生物的制备方法、含有该吡啶甲酰胺衍生物的药物组合物，以及该吡啶甲酰胺衍生物作为治疗剂的用途，特别是作为肾外髓钾通道(ROMK)的抑制剂和在制备治疗和/或预防高血压和心力衰竭的药物中的用途。
• Fused tricyclic heterocycle compounds and therapeutic uses thereof
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US11535633B2

  公开（公告）日：2022-12-27

  This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections.

  本申请公开了一类新的式(I)融合三环杂环化合物、其制备方法、包含这些化合物的药物组合物、其药学上可接受的盐、溶液剂或原药，以及它们在治疗有利于调节 STING 的疾病（如癌症、癌前病变和病毒感染）中的用途。
• [EN] PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES<br/>[FR] DÉRIVÉS DE CYCLES CONDENSÉS DE PARAZOLE ET PROCÉDÉ DE PRÉPARATION DE CES DERNIERS, ET APPLICATION DE CES DERNIERS DANS LE TRAITEMENT DE CANCERS, D'INFLAMMATION ET DE MALADIES IMMUNITAIRES<br/>[ZH] 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用
  申请人：BEIJING INNOCARE PHARMA TECH CO LTD

  公开号：WO2017128917A1

  公开（公告）日：2017-08-03

  本发明涉及吡唑稠环类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的新的衍生物及其可药用的盐或含有其的药物组合物、及其制备方法。本发明还涉及所述衍生物及其可药用的盐或含有其的药物组合物在制备治疗剂，特别是Bruton酪氨酸激酶抑制剂，和在制备治疗和/或预防肿瘤与免疫相关等疾病的药物中的用途。其中通式(I)的各取代基同说明书中的定义相同。
• PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US20170342059A1

  公开（公告）日：2017-11-30

  Pyridinecarboxamide derivatives, preparation methods, and a pharmaceutical uses thereof are provided. In particular, pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification are provided. Also provided are a preparation method for the pyridinecarboxamide derivatives of formula (I), a pharmaceutical composition containing the pyridinecarboxamide derivatives, and uses of the pyridinecarboxamide derivatives as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing hypertension and heart failure.
• FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US20210300944A1

  公开（公告）日：2021-09-30

  This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections.